A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

LOXO-783

Oral

DRUG

Fulvestrant

Intramuscular

DRUG

Imlunestrant

Oral

DRUG

Abemaciclib

Oral

DRUG

Anastrozole, Exemestane, or Letrozole

Oral

DRUG

Paclitaxel

Intravenous

Trial Locations (50)

1070

Institut Jules Bordet, Anderlecht

2010

St Vincent's Hospital, Sydney

3000

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

3002

Peter Maccallum Cancer Institute Erb, East Melbourne

5000

Cancer Research SA, Adelaide

5505

Asan Medical Center, Seoul

10065

Memorial Sloan Kettering Cancer Center, New York

14642

Wilmot Cancer Institute, Rochester

28007

Hospital General Universitario Gregorio Maranon, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28223

Hospital Quironsalud Madrid, Pozuelo de Alarcón

30322

Winship Cancer Center Emory University, Atlanta

32224

Mayo Clinic, Jacksonville

37203

Tennessee Oncology PLLC, Nashville

44805

Institut de Cancérologie de l'Ouest, Saint-Herblain

46010

Hospital Clinico Universitario de Valencia, Valencia

46015

Hospital Arnau de Vilanova Valencia, Valencia

63110

Washington University Medical School, St Louis

67033

ICANS_Institut de Cancerologie Strasbourg Europe, Strasbourg

69373

Centre Leon Berard, Lyon

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75248

Institut Curie, Paris

77030

University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

85259

Mayo Clinic of Scottsdale, Scottsdale

90095

UCLA Medical Center, Los Angeles

91054

Universitätsklinikum Erlangen, Erlangen

94158

UCSF Medical Center at Mission Bay, San Francisco

94305

Stanford University Hospital, Stanford

94805

Gustave Roussy, Villejuif

100036

Beijing Cancer hospital, Beijing

169610

National Cancer Centre Singapore, Singapore

200032

Fudan University Shanghai Cancer Center, Shanghai

330009

The Third Hospital of Nanchang, Nanchang

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

55905-0002

Mayo Clinic, Rochester

75390-8884

UT Southwestern Medical Center, Dallas

M5G 2M9

Princess Margaret Hospital (Hong Kong), Toronto

V5Z4E6

BC Cancer Vancouver, Vancouver

104-0045

National Cancer Center Hospital, Chūōku

135-8550

The Cancer Institute Hospital of JFCR, Kōtō City

606-8507

Kyoto University Hospital, Kyoto

464-8681

Aichi Cancer Center Hospital, Nagoya

06351

Samsung Medical Center, Seoul

08028

Hospital Universitario Quiron Dexeus, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

SW3 6JJ

Royal Marsden NHS Trust, London

SM2 5PT

Royal Marsden Hospital (Sutton), Sutton

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY